Introducing
RecombiMAb™ Recombinant Antibodies
We are excited to launch RecombiMAb™, our new
recombinant monoclonal antibody product line! RecombiMAb™ antibodies
are provided with mouse or human IgG constant regions instead of the
typical rat or hamster IgG constant regions. This means improved in
vivo activity and reduced immunogenicity in mouse and
humanized mouse models. In some syngeneic mouse tumor models,
particularly in BALB/c mice, repeated rat or hamster IgG administration
can result in complications due to hypersensitivity reactions. Using
the RecombiMAb™ antibody instead of the wild-type clone may reduce
antibody immunogenicity and alleviate hypersensitivity reactions in
susceptible mouse models.
Additionally, RecombiMAb™ recombinant antibodies
overcome the limitations of traditionally manufactured antibodies,
ensuring high lot-to-lot consistency and data reproducibility from
experiment to experiment. Learn
more about RecombiMAb™.
RecombiMAb™
are formulated for in vivo use and feature:
- Available Fc Domain
Silencing
- Over 95% purity
- Ultra-low endotoxin
levels (<1EU/mg)
- Preservative,
stabilizer, and carrier protein-free
- Murine pathogens and
protein aggregation screened
Featured RecombiMAb™ Antibodies:
|